Wall St. Cheat Sheet

Follow @wallstCS

Lansdowne Partners’ $100 Million Healthcare Sector Stock Allocation: MDVN, ELN, RGDX, CYTK, RIGL

November 28 2011 Tweet Email This

Wall St. Watchdog reveals information regarding Lansdowne Partners’ top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 5 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $100.288 million.

Medivation Inc. (NASDAQ:MDVN): On 06/30/2011, Lansdowne Partners reported holding 3,270,241 shares with a market value of $70,081,266. This comprised 1.05% of the total portfolio. On 09/30/2011, Lansdowne Partners reported holding 3,270,241 shares with a market value of $55,528,691. This comprised 0.97% of the total portfolio. The net change in shares for this position over the two quarters is 0. About Company: Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process.
Elan Corp. Plc (NYSE:ELN): On 06/30/2011, Lansdowne Partners reported holding 0 shares. On 09/30/2011, Lansdowne Partners reported holding 3,201,469 shares with a market value of $33,711,468. This comprised 0.59% of the total portfolio. The net change in shares for this position over the two quarters is 3,201,469. About Company: Elan Corporation plc is a specialty pharmaceutical company. The Group’s drug delivery technologies are designed to aid and control the absorption and utilization of active pharmaceutical compounds. Elan’s Pharmaceutical division focuses on the discovery, development and commercialization of products in the areas of acute care, pain management, infectious diseases and neurology.
Response Genetics Inc (NASDAQ:RGDX): On 06/30/2011, Lansdowne Partners reported holding 3,905,676 shares with a market value of $10,818,722. This comprised 0.16% of the total portfolio. On 09/30/2011, Lansdowne Partners reported holding 3,905,676 shares with a market value of $7,420,784. This comprised 0.13% of the total portfolio. The net change in shares for this position over the two quarters is 0. About Company: Response Genetics, Inc. is a biopharmaceutical company that researches and develops pharmacogenomic diagnostic tests. The Company’s products are targeted for potential use in the treatment of cancer.
Cytokinetics Inc. (NASDAQ:CYTK): On 06/30/2011, Lansdowne Partners reported holding 0 shares. On 09/30/2011, Lansdowne Partners reported holding 2,471,310 shares with a market value of $2,891,433. This comprised 0.05% of the total portfolio. The net change in shares for this position over the two quarters is 2,471,310. About Company: Cytokinetics, Incorporated is a biopharmaceutical company that combines life sciences and information technologies to accelerate and enhance the productivity of drug discovery and development. The Company focuses on the novel small molecule drugs that specifically target the cytoskeleton, a complex, dynamic framework that impacts all aspects of cell functions.
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL): On 06/30/2011, Lansdowne Partners reported holding 0 shares. On 09/30/2011, Lansdowne Partners reported holding 100,000 shares with a market value of $736,000. This comprised 0.01% of the total portfolio. The net change in shares for this position over the two quarters is 100,000. About Company: Rigel Pharmaceuticals, Inc. discovers and develops novel, small molecule drugs in four lead product development programs: allergy/asthma, autoimmune disorders, hepatitis C, and cancer. The Company’s first product candidate, R112, for allergic rhinitis is already in clinical testing. Rigel plans to begin clinical trials with the three additional drug candidates over the next 12 months.